Abstracts

Rifapentine Safety and PK with Novel Dosing Strategies to Increase Drug Exposures for TB: ACTG A5311

Background: Rifapentine (RPT) is a potent anti-tuberculosis (TB) drug poised to enter Phase 3 trials. Its sterilizing activity and treatment-shortening potential are exposure-dependent. To optimize exposures, RPT must be taken with food, and bioavailability declines with increased dose. Methodology: This phase 1, two-arm, open-label, multicenter trial in healthy HIV/TB-uninfected subjects investigated two strategies to increase…

HIV and Elevated Cancer-Specific Mortality Following Cancer Diagnosis in the UnitedStates

Background: HIV-infected individuals remain at increased cancer risk, despite advances in HIV treatment. In fact, prolonged life expectancy due to effective HIV treatment has resulted in greater numbers of HIV-infected persons reaching ages where cancer incidence is elevated. The combination of this increased opportunity to develop cancer at older ages as well as the established…

Impact of Kaposi Sarcoma on Survival in HIV-Infected African Adults on Antiretroviral Therapy

Background: In sub-Saharan Africa (SSA), Kaposi’s sarcoma (KS) remains one of the most common malignancies amongst HIV-infected adults. In resource-rich areas, we now know that survival after KS diagnosis has markedly improved in the ART era, and, in fact, ART alone is often initiated for KS in the absence of immediately life-threatening complications. In SSA,…

Prospective Characterization of Kaposi Sarcoma Herpesvirus Inflammatory Cytokine Syndrome

Background: Kaposi sarcoma herpesvirus (KSHV) is the cause of Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and a form of multicentric Castleman disease (MCD), each associated with HIV. Recently a novel KSHV-associated inflammatory syndrome distinct from KSHV-MCD was described: KSHV inflammatory cytokine syndrome (KICS). We report characteristics of the first ten patients prospectively studied with…

HIV-1 Infection Alters Intestinal Expression of Antiretroviral Drug Transporters and Enzymes

Background: HIV-1 infection is associated with intestinal tissue pathology and inflammation, which may alter the functional expression of drug transporters and metabolic enzymes known to be involved in antiretroviral drug disposition and intestinal absorption. This study investigated the effect of HIV-1 infection and/or chronic antiretroviral therapy on the expression of intestinal drug transporters and metabolic…

Tenofovir-Emtricitabine*Directly Observed Dosing: 100% Adherence Concentrations (HPTN 066)

Background: Oral pre-exposure prophylaxis trials have yielded disparate efficacy results attributed largely to variable adherence. Objective adherence benchmarks are needed. HPTN 066 was conducted to establish drug concentrations associated with 100% adherence by using directly observed tenofovir (TFV) disoproxil fumarate (TDF)/emtricitabine (FTC) dosing with variable frequency. Methodology: Healthy, HIV- men and women were randomized 1:1:1:1…

Pharmacokinetic Variability in TB Therapy: Associations with HIV and Effect on Outcome

Background: Inter-individual variability in exposure to anti-tuberculous drugs is well-described during therapy. However, relationships between pharmacokinetic parameters and clinical outcomes are poorly understood, particularly in HIV-endemic regions of southern Africa. Clinical pharmacokineticpharmacodynamic (PK-PD) studies are required to evaluate these associations and inform the development of shorter treatment regimens. Methodology: Adults with a first presentation of…